Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: August 24, 2012
Last updated: June 22, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)